Search - tctmd.com

Displaying 1 - 20 of 301

Sort: Relevancy | Date

News Daily News

Risk Calculators Miss Many Patients Who Present With First MI

Michael O'Riordan

November 21, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Daily News

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

Michael O'Riordan

September 23, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Trade-offs With Invasive Strategy in Older Patients With ACS: Meta-analysis

Michael O'Riordan

July 03, 2025

No Change in HF Outcomes When Private Equity Buys the Hospital

News Daily News

Private Equity-Backed Hospitals Appear to 'Cherry-Pick' HF Patients

Michael O'Riordan

June 16, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

Michael O'Riordan

February 24, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

News Daily News

Top Coronary Artery Disease News in 2024

Michael O'Riordan

December 26, 2024

Advertisement

Risk Calculators Miss Many Patients Who Present With First MI

CVD Still the Leading Cause of Death and Disease Globally

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Trade-offs With Invasive Strategy in Older Patients With ACS: Meta-analysis

Private Equity-Backed Hospitals Appear to 'Cherry-Pick' HF Patients

FDA Approves Triple Therapy Polypill for High Blood Pressure

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Top Coronary Artery Disease News in 2024

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content